https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy
EVgo reported Q1 FY24 earnings, surpassing estimates with a 118.2% Y/Y sales growth to $55.2 million. The uptick in revenue, fueled by charging and eXtend services, reflects the company's accelerating network throughput, hitting 53 GWh, a 194% Y/Y increase.
Amid Chapter 11 bankruptcy, Steward Health Care, Medical Properties Trust's tenant, faces financial turmoil. State regulators scrutinize its 30 hospitals, grappling with incidents like bat evacuations, unpaid nurses, and equipment shortages. Steward's reliance on MPW for a $300 million loan raises eyebrows, as stakeholders navigate complex ties amid regulatory interventions.
Esperion Therapeutics reports impressive Q1 revenues of $137.74 million, up 467% Y/Y, with EPS of $0.34, beating estimates. FDA approved expanded labels for NEXLETOL & NEXLIZET. Fiscal year 2024 revenue guidance: $225-$245 million.